2019
Siponimod Chips Away at Progressive MS
Longbrake EE, Hafler DA. Siponimod Chips Away at Progressive MS. Cell 2019, 179: 1440. PMID: 31951523, PMCID: PMC8023412, DOI: 10.1016/j.cell.2019.11.034.Peer-Reviewed Original ResearchMeSH KeywordsAzetidinesBenzyl CompoundsClinical Trials as TopicHumansMultiple SclerosisUnited StatesUnited States Food and Drug AdministrationConceptsProgressive multiple sclerosisGadolinium-enhancing MRI lesionsInflammatory disease activityImmunomodulatory medicationsDisability progressionDisease activityMRI lesionsProgressive MSNeurologic disabilityPMS patientsMultiple sclerosisSiponimodMedicationsSclerosisPatientsLesionsBedsideProgression
2016
The contemporary spectrum of multiple sclerosis misdiagnosis
Solomon AJ, Bourdette DN, Cross AH, Applebee A, Skidd PM, Howard DB, Spain RI, Cameron MH, Kim E, Mass MK, Yadav V, Whitham RH, Longbrake EE, Naismith RT, Wu GF, Parks BJ, Wingerchuk DM, Rabin BL, Toledano M, Tobin WO, Kantarci OH, Carter JL, Keegan BM, Weinshenker BG. The contemporary spectrum of multiple sclerosis misdiagnosis. Neurology 2016, 87: 1393-1399. PMID: 27581217, PMCID: PMC5047038, DOI: 10.1212/wnl.0000000000003152.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersBiomarkersClinical Trials as TopicDiagnostic ErrorsFemaleHumansImmunomodulationMaleMiddle AgedMultiple SclerosisUnited StatesConceptsMultiple sclerosisNeurologic symptomsMisdiagnosis of MSAcademic MS centersCorroborative objective evidenceMultiple sclerosis misdiagnosisDisease-modifying therapiesRadiographic diagnostic criteriaNonspecific neurologic symptomsMS therapyConsideration of symptomsCNS lesionsMRI abnormalitiesMS centersUnnecessary morbidityAlternate diagnosisMS attacksCorrect diagnosisDiagnostic criteriaPatientsMisdiagnosisObjective evidenceSymptomsTherapyDiagnosis
2013
Monoclonal Antibodies as Disease Modifying Therapy in Multiple Sclerosis
Longbrake EE, Parks BJ, Cross AH. Monoclonal Antibodies as Disease Modifying Therapy in Multiple Sclerosis. Current Neurology And Neuroscience Reports 2013, 13: 390. PMID: 24027005, PMCID: PMC3967547, DOI: 10.1007/s11910-013-0390-z.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedClinical Trials as TopicHumansImmunosuppressive AgentsMultiple Sclerosis